Evidence map›Paper›PMID 37353740›Full record

ArticleBMC cancer2023

Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C-ProMeta-1).

Tarek Al-Hammouri, Ricardo Almeida-Magana, Rachel Lawrence, Tom Duffy, Laura White, Edwina Burke, Sakunthala Kudahetti, Justin Collins, Prabhakar Rajan, Daniel Berney and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Tarek Al-Hammouri *Dept. of Urology, University College London Hospitals, London, UK.
Ricardo Almeida-Magana *Dept. of Urology, University College London Hospitals, London, UK.
Rachel LawrenceQueen Mary University of London, Barts Cancer Institute, London, UK.
Tom DuffyQueen Mary University of London, Wolfson Institute of Population Health, London, UK.
Laura WhiteQueen Mary University of London, Wolfson Institute of Population Health, London, UK.
Edwina BurkeQueen Mary University of London, Barts Cancer Institute, London, UK.
Sakunthala KudahettiQueen Mary University of London, Barts Cancer Institute, London, UK.
Justin CollinsDept. of Urology, University College London Hospitals, London, UK.
Prabhakar RajanDept. of Urology, University College London Hospitals, London, UK.
Daniel BerneyQueen Mary University of London, Barts Cancer Institute, London, UK.
Rhian GabeQueen Mary University of London, Wolfson Institute of Population Health, London, UK. r.gabe@qmul.ac.uk.
Greg ShawDept. of Urology, University College London Hospitals, London, UK. gregshaw@nhs.net.
Yong-Jie LuQueen Mary University of London, Barts Cancer Institute, London, UK. y.j.lu@qmul.ac.uk.
Queen Mary University of London · GBRoyal London Hospital · GBUniversity College London · GB

Funding

Prostate Cancer UK MA-CT20-011
6 · The paper itself

Abstract

backgroundTreatment decisions in prostate cancer (PCa) rely on disease stratification between localised and metastatic stages, but current imaging staging technologies are not sensitive to micro-metastatic disease. Circulating tumour cells (CTCs) status is a promising tool in this regard. The Parsortix® CTC isolation system employs an epitope-independent approach based on cell size and deformability to increase the capture rate of CTCs. Here, we present a protocol for prospective evaluation of this method to predict post radical prostatectomy (RP) PCa cancer recurrence.

methodsWe plan to recruit 294 patients diagnosed with unfavourable intermediate, to high and very high-risk localised PCa. Exclusion criteria include synchronous cancer diagnosis or prior PCa treatment, including hormone therapy. RP is performed according to the standard of care. Two blood samples (20 ml) are collected before and again 3-months after RP. The clinical team are blinded to CTC results and the laboratory researchers are blinded to clinical information. Treatment failure is defined as a PSA ≥ 0.2 mg/ml, start of salvage treatment or imaging-proven metastatic lesions. The CTC analysis entails enumeration and RNA analysis of gene expression in captured CTCs. The primary outcome is the accuracy of CTC status to predict post-RP treatment failure at 4.5 years. Observed sensitivity, positive and negative predictive values will be reported. Specificity will be presented over time. DISCUSSION: CTC status may reflect the true potential for PCa metastasis and may predict clinical outcomes better than the current PCa progression risk grading systems. Therefore establishing a robust biomarker for predicting treatment failure in localized high-risk PCa would significantly enhance guidance in treatment decision-making, optimizing cure rates while minimizing unnecessary harm from overtreatment.

trial registrationISRCTN17332543.

Indexed as

Neoplastic Cells, CirculatingProstatic NeoplasmsHumansMaleNeoplasm Recurrence, LocalProspective StudiesProstatectomyProstate-Specific AntigenTreatment FailureProstate-Specific AntigenCirculating tumour cellsMicro-metastasisProstate cancerRadical prostatectomy

Identifiers

PMID37353740
PMCPMC10288675
OpenAlexW4381805823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.